HomeCONGRESS

CONGRESS

View Category
Day 3

FREEDOM: Insulin dependent versus non-insulin dependent with multivessel disease

From the total of 1900 patients in the FREEDOM study, 1248 did not require insulin (631 received...
solaci -
Learn More
Day 3

DUTCH PEERS: Everolimus DES versus zotarolimus DES

This study randomized 1:1,  906 patients to receive zotarolimus-eluting stent and 905 patients to receive everolimus-eluting stent....
solaci -
Learn More
Day 3

OPTIMIZE: 3 versus 12 months dual antiplatelet therapy after angioplasty with DES

Currently the recommendation is 12 months of dual antiplatelet after a drug-eluting stent angioplasty. This study compared...
solaci -
Learn More
Day 3

MOZART: IVUS reduces contrast volume needed for angioplasty

Contrast nephropathy is associated with increased morbidity and so this study evaluates the possibility of reducing the...
solaci -
Learn More
Day 2

ADVISE II: iFFR comparable toFFRbut with out adenosine

Several studies tested the utility of fractional flow reserve (FFR) to assess coronary lesions functionally. The FFR...
solaci -
Learn More
Day 2

CHILL-MI: Hypothermia fails to show benefit in patients with acute ST- elevation IAM.

Hypothermia improves myocardial ischemia in animals but studies in humans failed to demonstrate benefit to that extent.We...
solaci -
Learn More
Day 2

SMART-CASE: Angiographic Guidanceangioplastyto >50% versus >70% lesions.

This prospective randomized study compared aggressive revascularization angiography injuries 50% versus a most conservative revascularization lesions>70%.The primary...
solaci -
Learn More
Day 2

RIBS V: Pharmacological balloon vs second-generation drug-eluting stent in the treatment of BMS restenosis

The ideal therapy for treating in-stent restenosis continues to be debated . The pharmacological balloons showed good...
solaci -
Learn More